Showing results (1-10 of 52) with videos related to
Sort By:
Pageof 6
Alzheimer'S Research & Therapy|December 20, 2013
Rivastigmine in moderately severe-to-severe Alzheimer's disease: Severe Impairment Battery factor analysisSteven Ferris, Stella Karantzoulis, Monique Somogyi, et al.International Journal of Geriatric Psychiatry|November 23, 2006
A double-blind, placebo-controlled trial of memantine in age-associated memory impairment (memantine in AAMI)Steven Ferris, Lon Schneider, Mildred Farmer, et al.American Journal of Alzheimer'S Disease and Other Dementias|September 16, 2015
Cognitive Efficacy (SIB) of 13.3 Versus 4.6 mg/24 h Rivastigmine Patch in Severe Alzheimer's DiseaseRichard S Isaacson, Steven Ferris, Drew M Velting, et al.Pharmacogenetics and Genomics|July 21, 2009
Progression from mild cognitive impairment to Alzheimer's disease: effects of sex, butyrylcholinesterase genotype, and rivastigmine treatmentSteven Ferris, Agneta Nordberg, Hilkka Soininen, et al.International Journal of Geriatric Psychiatry|March 9, 2011
Detecting treatment effects with combinations of the ADAS-cog items in patients with mild and moderate Alzheimer's diseaseRalf Ihl, Steven Ferris, Philippe Robert, et al.Alzheimer'S Research & Therapy|August 28, 2010
Review of Alzheimer's disease scales: is there a need for a new multi-domain scale for therapy evaluation in medical practice?Philippe Robert, Steven Ferris, Serge Gauthier, et al.Journal of Geriatric Psychiatry and Neurology|May 14, 2008
Learning and generalization tasks predict short-term cognitive outcome in nondemented elderlyCatherine E Myers, Alan Kluger, James Golomb, et al.The New England Journal of Medicine|April 4, 2003
Memantine in moderate-to-severe Alzheimer's diseaseBarry Reisberg, Rachelle Doody, Albrecht Stöffler, et al.Gender Medicine|August 18, 2009
Effects of gender on response to treatment with rivastigmine in mild cognitive impairment: A post hoc statistical modeling approachSteven Ferris, Roger Lane, Nikolaos Sfikas, et al.Archives of Neurology|January 13, 2006
A 24-week open-label extension study of memantine in moderate to severe Alzheimer diseaseBarry Reisberg, Rachelle Doody, Albrecht Stöffler, et al.Pageof 6